Levente Meszaros
Corporate Officer/Principal bij RADIOPHARM THERANOSTICS LIMITED
Actieve functies van Levente Meszaros
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| RADIOPHARM THERANOSTICS LIMITED | Corporate Officer/Principal | 01-01-2022 | - |
NanoMab Technology Ltd.
 NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | Hoofd Techniek/Wetenschap/O&O | - | - |
Loopbaan van Levente Meszaros
Statistieken
Internationaal
| China | 2 |
| Australië | 2 |
Operationeel
| Corporate Officer/Principal | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoraal
| Health Technology | 2 |
| Health Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| RADIOPHARM THERANOSTICS LIMITED | Health Services |
| Bedrijven in privébezit | 1 |
|---|---|
NanoMab Technology Ltd.
NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | Health Technology |
- Beurs
- Insiders
- Levente Meszaros
- Ervaring
